ARWR · Arrowhead Pharmaceuticals, Inc.

Track ARWR — free

$62.00 -0.35 (-0.56%)

S&P 400 member Russell 1000 member Rebalance outlook locked

Market Cap

$9.36B

141.25M

Volume · Oct 6 819.21K Avg daily vol (3M) 1.91M

Up next

Next earnings call

Nov 2, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 4, 2026

Q3 2026 earnings call transcript

call held Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$669.50M

Trailing 12 months

Net income (TTM)

−$315.24M

Trailing 12 months

Revenue growth YoY

+171.0%

Year over year

Operating margin

-33.8%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-0.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+3.1%

Year over year · more shares

Price change (1Y)

+85.5%

Trailing year

Short interest

6.6%

Latest settlement · 5.2 days to cover

View all 115 metrics

AI Brief

Q3 FY26 earnings call · Aug 4, 2026

Q3 FY26

TL;DR. Arrowhead reported positive SHASTA-3 and SHASTA-4 Phase 3 topline results supporting a plozasiran sNDA in SHTG, acquired a priority review voucher to accelerate that submission, and continued to expand REDEMPLO's commercial footprint in FCS including EU and Australia approvals, while net loss widened to $194.3M and operating expenses rose year-over-year.

Bullish

+ SHASTA-3 and SHASTA-4 both met primary and all pre-specified secondary endpoints with 79% and 81% median triglyceride reductions
+ Plozasiran reduced acute pancreatitis events by 78% across SHTG and 100% in the highest-risk subgroup
+ REDEMPLO received marketing authorization in the EU and Australia, expanding approved footprint to five geographies
+ Madrigal license deal brings $25M upfront plus up to $975M in milestones and tiered royalties
+ Cash and investments of approximately $1.6 billion provide funding flexibility

Bearish

− Net loss widened to $194.3M ($1.36/share) from $175.2M a year ago
− Total operating expenses rose ~$52M year-over-year to $245M, with R&D up ~$36M and SG&A up ~$16M
− Pre-specified MRI-PDFF subgroup showed no statistically significant difference in liver fat between plozasiran and placebo

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High

Market backdrop VIX 15.5 · calm Equity put/call 0.59

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −14%

below

Price vs 50-day avg −22%

below

RSI (14) 28

oversold

MACD trend Negative

52-week position 50%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −28%

trailing

6-month return −7%

trailing

YTD return −6%

this year

Relative strength −18%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $80 › 200d $72 — 50d above 200d

Institutional flow Distributing

2 of 509 funds reported for Sep 30 · net -202 sh shares

Insider flow Distributing

Net -$1.2M over 90 days · 100% sells

Short interest Falling

6.56% of float · ▼ -1.6% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

509 holders — near 3-yr high, broad support

Squeeze score 55

elevated · 0–100

Fundamentals

Strong

Revenue growth −49%

Y/Y

EPS growth +100%

Y/Y

Free cash flow $156.9M

Quant / Vol

risk profile

Very High

Volatility 62%

annualized · 1-yr

Max drawdown −30%

past year

ATR 5.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed May 7, 2020

Remaining deferred revenue to be recognized · this calendar year $33.2M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−14% Bearish

Price vs 50-day avg

−22% Bearish

RSI (14)

28 Neutral

MACD trend

Negative Bearish

52-week position

50% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Mixed

Trend (MA cross) No cross

50d $80 › 200d $72 — 50d above 200d

Institutional flow Distributing

2 of 509 funds reported for Sep 30 · net -202 sh shares

Insider flow Distributing

Net -$1.2M over 90 days · 100% sells

Short interest Falling

6.56% of float · ▼ -1.6% MoM · 5.2 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

509 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $35 Now $62 · 50% Range high $90

vs 200-day avg -14% vs 50-day avg -22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ARWR Arrowhead Pharmaceuticals, Inc. this stock	$9.36B	-6.1%	-48.6%	—	6.6%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.1%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-5.9%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+589.1%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

509

% held: 86.3%
Reported: 2 of 509
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

496

View

Short & Settlement

Short Interest Falling

Shares short

9.3M

Days to cover: 5.2d
Change: -154.2K sh

View

Short Volume

Short vol %

42%

As of: Oct 5, 2026

Short Total

View

Fails to Deliver

FTD shares

16.5K

Value: $1.5M
As of: Aug 19, 2026

View

Off-Exchange

Off-exchange %

45.1%

Week of: Aug 31, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$1.2M

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Congressional Trades Sell

Member

Daniel Goldman

Amount: $1.0K–$15.0K
Traded: Jan 31, 2023

View

Financials

Revenue (FY)

$829.4M

Net income (FY): $-1.6M
EPS diluted: $-0.01

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 15, 2026
This year: 15

View

Proposed Sales

Value

$641.9K

Shares: 10.0K
Filed: Mar 5, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 15, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
ARWR	-4.8%	-27.8%	-6.5%	-4.7%	-6.1%
SPY	+1.2%	+0.6%	+11.6%	+1.6%	+13.6%
vs SPY	-6.0%	-28.4%	-18.1%	-6.3%	-19.7%

Key facts CIK 879407 CUSIP 04280A100 13F (30d) 10 filings 10 filers Visit website Investor relations

ARWR · Arrowhead Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance